Pharma BD Deal Intelligence
Roche obtained a worldwide license to develop and commercialize camonsertib (RP-3500), Repare's ATR inhibitor targeting cancers with specific DNA damage repair deficiencies (synthetic lethality approach). Roche paid $125 million upfront with up to $1.2 billion in milestone payments. Deal was terminated in February 2024 when Roche returned global rights to Repare, just weeks after a $40 million clinical milestone payment for first patient dosing in the Tapistry Phase II trial. Post-termination, Repare was unable to re-partner camonsertib with another large pharma: it announced a portfolio re-prioritization in January 2025, out-licensed the separate PKMYT1 inhibitor lunresertib (not camonsertib) to Debiopharm in July 2025, and was ultimately acquired by nonprofit XenoTherapeutics, Inc. — a deal completed January 28, 2026 (~US$2.20/share in cash plus a contingent value right) that took Repare private.